Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes
Thamer A Almangour, Estefany Garcia, Qi Zhou, Alan Forrest, Keith S Kaye, Jian Li, Tony Velkov, Gauri G Rao
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | ELSEVIER | Published : 2021
The global rise in nosocomial pneumonia caused by multidrug-resistant (MDR) Gram-negative pathogens and the increasingly limited antibiotic treatment options are growing threats to modern medicine. As a result, older antibiotics such as polymyxins are being used as last-resort drugs for MDR nosocomial pneumonia. Polymyxins are bactericidal against most aerobic Gram-negative bacilli. High-dose intravenous (IV) adminsitration of polymyxins, however, results in subtherapeutic concentrations at the site of infection making treatment challenging. Alternative forms of polymyxin delivery have been considered in order to better achieve the necessary concentrations at the site of infection. Several s..View full abstract
Awarded by National Institute of Allergy and Infectious Diseases of the National Institute of Health
Awarded by National Institute of General Medical Sciences of the National Institutes of Health
QZ, JL, TV and GGR were supported by the National Institute of Allergy and Infectious Diseases of the National Institute of Health [award number R01AI132681]. EG was supported by the National Institute of General Medical Sciences of the National Institutes of Health [award number T32GM086330]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.